View Item 

Show simple item record

Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond
dc.contributor.authorBree, Remco
dc.contributor.authorWolf, Gregory T.
dc.contributor.authorde Keizer, Bart
dc.contributor.authorNixon, Iain J.
dc.contributor.authorHartl, Dana M.
dc.contributor.authorForastiere, Arlene A.
dc.contributor.authorHaigentz, Missak
dc.contributor.authorRinaldo, Alessandra
dc.contributor.authorRodrigo, Juan P.
dc.contributor.authorSaba, Nabil F.
dc.contributor.authorSuárez, Carlos
dc.contributor.authorVermorken, Jan B.
dc.contributor.authorFerlito, Alfio
dc.date.accessioned2017-10-23T17:31:21Z
dc.date.available2019-01-07T18:34:38Zen
dc.date.issued2017-11
dc.identifier.citationBree, Remco; Wolf, Gregory T.; de Keizer, Bart; Nixon, Iain J.; Hartl, Dana M.; Forastiere, Arlene A.; Haigentz, Missak; Rinaldo, Alessandra; Rodrigo, Juan P.; Saba, Nabil F.; Suárez, Carlos ; Vermorken, Jan B.; Ferlito, Alfio (2017). "Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond." Head & Neck 39(11): 2329-2349.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/138890
dc.description.abstractSignificant correlations between the response to induction chemotherapy and success of subsequent radiotherapy have been reported and suggest that the response to induction chemotherapy is able to predict a response to radiotherapy. Therefore, induction chemotherapy may be used to tailor the treatment plan to the individual patient with head and neck cancer: following the planned subsequent (chemo)radiation schedule, planning a radiation dose boost, or reassessing the modality of treatment (eg, upfront surgery). Findings from reported trials suggest room for improvement in clinical response assessment after induction chemotherapy, but an optimal method has yet to be identified. Historically, indices of treatment efficacy in solid tumors have been based solely on systematic assessment of tumor size. However, functional imaging (eg, fluorodeoxyglucose‐positron emission tomography (FDG‐PET) potentially provides an earlier indication of response to treatment than conventional imaging techniques. More advanced imaging techniques are still in an exploratory phase and are not ready for use in clinical practice.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherfluorodeoxyglucose‐positron emission tomography (FDG‐PET)
dc.subject.otherhead and neck squamous cell carcinoma
dc.subject.otherinduction chemotherapy
dc.subject.otherresponse assessment
dc.titleResponse assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138890/1/hed24883_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138890/2/hed24883.pdf
dc.identifier.doi10.1002/hed.24883
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceArgiris A, Heron DE, Smith RP, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010; 28: 5294 – 5300.
dc.identifier.citedreferenceIssa MR, Samuels SE, Bellile E, Shalabi FL, Eisbruch A, Wolf G. Tumor volumes and prognosis in laryngeal cancer. Cancers (Basel). 2015; 7: 2236 – 2261.
dc.identifier.citedreferencePowell C, Schmidt M, Borri, et al. Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient‐based treatment regimens for advanced head and neck cancer. Radiother Oncol. 2013; 106: 112 – 117.
dc.identifier.citedreferenceBjurberg M, Henriksson E, Brun E, et al. Early changes in 2‐deoxy‐2‐[18F]fluoro‐D‐glucose metabolism in squamous‐cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm. 2009; 24: 327 – 332.
dc.identifier.citedreferenceAbgral R, Le Roux PY, Keromnes N, et al. Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5‐fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2012; 39: 1839 – 1847.
dc.identifier.citedreferenceBoellaard R. Need for standardization of 18F‐FDG PET/CT for treatment response assessments. J Nucl Med. 2011; 52 Suppl 2: 93S ‐ 100S.
dc.identifier.citedreferenceHyun OJ, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016; 280: 576 – 584.
dc.identifier.citedreferenceDalsaso TA, Lowe VJ, Dunphy FR, Martin DS, Boyd JH, Stack BC. FDG‐PET and CT in evaluation of chemotherapy in advanced head and neck cancer. Clin Positron Imaging. 2000; 3: 1 – 5.
dc.identifier.citedreferenceBrun E, Kjellén E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002; 24: 127 – 135.
dc.identifier.citedreferenceMcCollum AD, Burrell SC, Haddad RI, et al. Positron emission tomography with 18F‐fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004; 26: 890 – 896.
dc.identifier.citedreferenceKikuchi M, Shinohara S, Nakamoto Y, et al. Sequential FDG‐PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma. Mol Imaging Biol. 2011; 13: 368 – 377.
dc.identifier.citedreferenceKikuchi M, Nakamoto Y, Shinohara S, et al. Early evaluation of neoadjuvant chemotherapy response using FDG‐PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. Int J Clin Oncol. 2013; 18: 402 – 410.
dc.identifier.citedreferenceYoon DH, Cho Y, Kim SY, et al. Usefulness of interim FDG‐PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011; 81: 118 – 125.
dc.identifier.citedreferenceYu J, Cooley T, Truong MT, Mercier G, Subramaniam RM. Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. J Med Imaging Radiat Oncol. 2014; 58: 18 – 24.
dc.identifier.citedreferenceGavid M, Prevot‐Bitot N, Timoschenko A, Gallet P, Martin C, Prades JM. [18F]‐FDG PET‐CT prediction of response to induction chemotherapy in head and neck squamous cell carcinoma: preliminary findings. Eur Ann Otorhinolaryngol Head Neck Dis. 2015; 132: 3 – 7.
dc.identifier.citedreferenceSemrau S, Schmidt D, Lell M, et al. Results of chemoselection with short induction chemotherapy followed by chemoradiation or surgery in the treatment of functionally inoperable carcinomas of the pharynx and larynx. Oral Oncol. 2013; 49: 454 – 460.
dc.identifier.citedreferenceWong KH, Panek R, Welsh L, et al. The predictive value of early assessment after 1 cycle of induction chemotherapy with 18F‐FDG PET/CT and diffusion‐weighted MRI for response to radical chemoradiotherapy in head and neck squamous cell carcinoma. J Nucl Med. 2016; 57: 1843 – 1850.
dc.identifier.citedreferenceDos Anjos RF, Dos Anjos DA, Vieira DL, Leite AF, Figueiredo PT, de Melo NS. Effectiveness of FDG‐PET/CT for evaluating early response to induction chemotherapy in head and neck squamous cell carcinoma: a systematic review. Medicine (Baltimore). 2016; 95: e4450.
dc.identifier.citedreferenceKolff‐Gart AS, Pouwels PJ, Noij DP, et al. Diffusion‐weighted imaging of the head and neck in healthy subjects: reproducibility of ADC values in different MRI systems and repeat sessions. AJNR Am J Neuroradiol. 2015; 36: 384 – 390.
dc.identifier.citedreferenceBerrak S, Chawla S, Kim S, et al. Diffusion weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy. Acad Radiol. 2011; 18: 1225 – 1232.
dc.identifier.citedreferenceGuo W, Luo D, Lin M, et al. Pretreatment intra‐voxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI) in predicting induction chemotherapy response in locally advanced hypopharyngeal carcinoma. Medicine (Baltimore). 2016; 95: e3039.
dc.identifier.citedreferenceGandhi D, Hoeffner EG, Carlos RC, Case I, Mukherji SK. Computed tomography perfusion of squamous cell carcinoma of the upper aerodigestive tract. Initial results. J Comput Assist Tomogr. 2003; 27: 687 – 693.
dc.identifier.citedreferenceGandhi D, Chepeha DB, Miller T, et al. Correlation between initial and early follow‐up CT perfusion parameters with endoscopic tumor response in patients with advanced squamous cell carcinomas of the oropharynx treated with organ‐preservation therapy. AJNR Am J Neuroradiol. 2006; 27: 101 – 106.
dc.identifier.citedreferencePetralia G, Preda L, Giugliano G, et al. Perfusion computed tomography for monitoring induction chemotherapy in patients with squamous cell carcinoma of the upper aerodigestive tract: correlation between changes in tumor perfusion and tumor volume. J Comput Assist Tomogr. 2009; 33: 552 – 559.
dc.identifier.citedreferenceSchwartz LH, Seymour L, Litière S, et al. RECIST 1.1 ‐ Standardisation and disease‐specific adaptations: perspectives from the RECIST Working Group. Eur J Cancer. 2016; 62: 138 – 145.
dc.identifier.citedreferenceBradford CR, Wolf GT, Carey TE, et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg. 1999; 121: 534 – 538.
dc.identifier.citedreferenceMoreno‐Galindo C, Hermsen M, García‐Pedrero JM, Fresno MF, Suárez C, Rodrigo JP. p27 and BCL2 expression predicts response to chemotherapy in head and neck squamous cell carcinomas. Oral Oncol. 2014; 50: 128 – 134.
dc.identifier.citedreferenceFerris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous‐cell carcinoma of the head and neck. N Engl J Med. 2016; 375: 1856 – 1867.
dc.identifier.citedreferenceChow LQ, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker‐unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE‐012 expansion cohort. J Clin Oncol. 2016.
dc.identifier.citedreferenceBauman JE, Cohen E, Ferris RL, et al. Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017; 123: 1259 – 1271.
dc.identifier.citedreferenceTarpley JL, Chretien PB, Alexander JC Jr, Hoye RC, Block JB, Ketcham AS. High dose methotrexate as a preoperative adjuvant in the treatment of epidermoid carcinoma of the head and neck. A feasibility study and clinical trial. Am J Surg. 1975; 130: 481 – 486.
dc.identifier.citedreferenceLaccourreye O, Veivers D, Hans S, Ménard M, Brasnu D, Laccourreye H. Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1‐T4N0M0 complete clinical responders. Cancer. 2001; 92: 1504 – 1511.
dc.identifier.citedreferenceHartl DM, Brasnu DF. Chemotherapy alone for glottic carcinoma: a need for higher‐level evidence. Ann Otol Rhinol Laryngol. 2009; 118: 543 – 545.
dc.identifier.citedreferenceHaigentz M Jr, Cohen EE, Wolf GT, Strojan P, Eisbruch A, Ferlito A. The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2012; 48: 1065 – 1067.
dc.identifier.citedreferencePignon JP, le Maître A, Maillard E, Bourhis J; on behalf of the MACH‐NC Collaborative Group. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4 – 14.
dc.identifier.citedreferenceMa J, Liu Y, Yang X, Zhang CP, Zhang ZY, Zhong LP. Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta‐analysis. World J Surg Oncol. 2013; 11: 67.
dc.identifier.citedreferenceBlanchard P, Baujat B, Holostenco V, et al. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011; 100: 33 – 40.
dc.identifier.citedreferenceDepartment of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685 – 1690.
dc.identifier.citedreferenceLefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996; 88: 890 – 899.
dc.identifier.citedreferenceLefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009; 101: 142 – 152.
dc.identifier.citedreferenceEnsley JF, Jacobs JR, Weaver A, et al. Correlation between response to cisplatinum‐combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer. 1984; 54: 811 – 814.
dc.identifier.citedreferenceUrba S, Wolf G, Eisbruch A, et al. Single‐cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006; 24: 593 – 598.
dc.identifier.citedreferenceMarur S, Li S, Cmelak AJ, et al. E1308: Phase II trial of induction chemotherapy followed by reduced‐dose radiation and weekly cetuximab in patients with HPV‐associated resectable squamous cell carcinoma of the oropharynx‐ ECOG‐ACRIN Cancer Research Group. J Clin Oncol. 2016.
dc.identifier.citedreferenceRose BS, Winer EP, Mamon HJ. Perils of the pathologic complete response. J Clin Oncol. 2016; 34: 3959 – 3962.
dc.identifier.citedreferenceMiller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207 – 214.
dc.identifier.citedreferenceTherasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205 – 216.
dc.identifier.citedreferenceEisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228 – 247.
dc.identifier.citedreferenceYoung H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]‐fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35: 1773 – 1782.
dc.identifier.citedreferenceShankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F‐FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006; 47: 1059 – 1066.
dc.identifier.citedreferenceWahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1: 122S ‐ 150S.
dc.identifier.citedreferenceHaigentz M Jr, Silver CE, Rinaldo A, Ferlito A. Definitive chemotherapy: a new frontier in the fight against laryngeal cancer. Eur Arch Otorhinolaryngol. 2010; 267: 1 – 4.
dc.identifier.citedreferenceAdjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. Cancer. 1987; 60: 301 – 311.
dc.identifier.citedreferenceSchuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope. 1988; 98: 1205 – 1211.
dc.identifier.citedreferenceJortay A, Demard F, Dalesio O, et al. A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation. Results from 5 to 10 years. Acta Chir Belg. 1990; 90: 115 – 122.
dc.identifier.citedreferenceRichard JM, Kramar A, Molinari R, et al. Randomised EORTC head and neck cooperative group trial of preoperative intra‐arterial chemotherapy in oral cavity and oropharynx carcinoma. Eur J Cancer. 1991; 27: 821 – 827.
dc.identifier.citedreferencePaccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst. 1994; 86: 265 – 272.
dc.identifier.citedreferenceVolling P, Schroder M, Muller R, Ebeling O, Quirin R, Stennert E. Induction chemotherapy in primary resectable head and neck tumors ‐ a prospective randomized trial. Int J Oncol. 1994; 4: 909 – 914.
dc.identifier.citedreferenceMaipang T, Maipang M, Geater A, Panjapiyakul C, Watanaarepornchai S, Punperk S. Combination chemotherapy as induction therapy for advanced resectable head and neck cancer. J Surg Oncol. 1995; 59: 80 – 85.
dc.identifier.citedreferenceLewin F, Damber L, Jonsson H, et al. Neoadjuvant chemotherapy with cisplatin and 5‐fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol. 1997; 43: 23 – 28.
dc.identifier.citedreferenceRichard JM, Sancho‐Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998; 34: 224 – 228.
dc.identifier.citedreferenceKohno N, Ikari T, Kawaida M, et al. Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of the head and neck. Jpn J Clin Oncol. 2000; 30: 253 – 258.
dc.identifier.citedreferenceDomenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tête et du Cou (GETTEC). Br J Cancer. 2000; 83: 1594 – 1598.
dc.identifier.citedreferenceLicitra L, Grandi C, Guzzo M, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol. 2003; 21: 327 – 333.
dc.identifier.citedreferenceVermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695 – 1704.
dc.identifier.citedreferenceLorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous‐cell cancer of the head and neck: long‐term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011; 12: 153 – 159.
dc.identifier.citedreferenceLefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013; 31: 853 – 859.
dc.identifier.citedreferenceChepeha DB, Sacco AG, Oxford LE, et al. Advanced squamous cell carcinoma of the oropharynx: efficacy of positron emission tomography and computed tomography for determining primary tumor response during induction chemotherapy. Head Neck. 2009; 31: 452 – 460.
dc.identifier.citedreferenceZhong LP, Zhang CP, Ren GX, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up‐front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013; 31: 744 – 751.
dc.identifier.citedreferenceMoertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976; 38: 388 – 394.
dc.identifier.citedreferenceWeber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005; 46: 983 – 995.
dc.identifier.citedreferencePatil V, Noronha V, Joshi A, et al. Is there a limitation of RECIST criteria in prediction of pathological response, in head and neck cancers, to postinduction chemotherapy? ISRN Oncol. 2013; 2013: 259154.
dc.identifier.citedreferenceBaghi M, Mack MG, Hambek M, et al. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. Head Neck. 2007; 29: 104 – 108.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed24883_am.pdf
Size:
361.9KB
Format:
PDF
View/Open
Name:
hed24883.pdf
Size:
661.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.